000			02171nam a22002537a 4500
003			OSt
005			20240305192305.0
008			220121b |||||||| |||| 00| 0 eng d
020			_a9789400942554
020			_a9400942559
040			_cData Centre
100			_a Dimitrios G. Oreopoulos _929046
245			_aGeriatric Nephrology _bThe medical, psychosocial, nursing, financial and ethical issues of treating end-stage renal disease in the elderly
250			_a illustrated
260			_aFalcon House, Queen Square, Lancaster LA1 1RN, UK _bSpringer Science & Business Media _c 2012
300			_a293 pages
490			_v Volume 12 of Developments in Nephrology
520			_aThe year was 1943. As a third-year medical student at Stanford, I was about to witness the beginning of a medical miracle. Dr. Arthur Bloomfield, Professor of Medicine, had selected my patient, a middle aged man, who was dying of acute pneumococcal pneumonia, as one of the first patients to receive miniscule doses (by today's standards) of his meagre supply of a new drug - penicillin. The patient's response amazed everyone especially this impressionable medical student. The rest of the story is history. With one stroke, the introduction of penicillin removed from the medical scene the 'friend of the aged' - lobar pneumonia. The consequences, which no one could have imagined at the time, are still becoming manifest as other 'miracles' such as respirators, artificial kidneys and many potent new antibiotics have come upon the scene. All of us are aware that these miracles have created a variety of new challenges around the states of dying and near dying. We have no easy answers for these problems. Nevertheless as dialysis techniques, especially CAPD, are applied more widely to the treatment of the elderly, the task of helping the patient meet death with dignity becomes increasingly important and vexing because once begun, dialysis is difficult to terminate.
600			_xMedical / Nephrology _928626
600			_xMedical / Geriatrics _929047
600			_x Medical / Clinical Medicine _926816
600			_x Medical › Nephrology _928627
942			_2ddc _cEB
999			_c4231 _d4231